The P-IIb study assesses the safety & efficacy of enobosarm (3mg, 6mg) or PBO to treat conserving muscle & augment fat loss among patients (n=~90) with sarcopenic obesity or overweight patients (>60yrs.) administered with Wegovy. Topline data is anticipated in Q4’24
The 1EP is total lean body mass difference while the 2EPs are changes in total body fat mass & physical function at 16wks.
After dose-finding part, the patients will enter into P-IIb extension study under which GLP-1 RA will be discontinued & enobosarm will be administered for another 12wks. to assess the ability of sustaining muscle mass and preventing fat & weight gain post GLP-1 RA discontinuation. Topline results are anticipated in Q2’25
Ref: Veru | Image: Veru
Related News:- Valeo Pharma Enters into a Commercial Services Agreement with Veru for Sabizabulin to Treat COVID-19 in Canada
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
